Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE

Herbert Struemper 1, Milena Kurtinecz, Lisa Edwards, William W Freimuth, David A Roth, William Stohl

ABSTRACT

Objective To examine the long-term changes in circulating B cell subsets and IgG levels at 5+ years of continuous belimumab treatment and their correlations with efficacy and safety measures.

Methods This was a post hoc analysis of a continuation study (BEL112233; NCT00724867) of eligible US patients who completed the 76-week BLISS-76 Study (BEL110751; NCT00410384), with up to eight calendar-years of follow-up and median (IQR) belimumab exposure of 310 (209, 364) weeks. From week 76, patients initially randomised to intravenous belimumab 1 mg/kg or 10 mg/kg every 4 weeks in BLISS-76 continued to receive the same dose in the continuation study, while those initially randomised to placebo received belimumab 10 mg/kg intravenously every 4 weeks during continuation. All patients continued to receive standard SLE therapy. Biomarker data were collected, and the effects on baseline and early changes (weeks 0–24 after starting belimumab) from baseline in biomarkers on SLE Responder Index (SRI-4) and infection rate were evaluated.

Results Of the 819 patients from BLISS-76, 268 self-selecting patients entered BEL112233. Compared with baseline, B cell subset counts decreased by 40%–99% after 312 weeks (6 years), and serum IgG levels decreased by 28% after 284 weeks. Higher baseline naive B cell counts were associated with greater SRI-4 response rates (p<0.05), whereas higher baseline SLE subset plasma and short-lived plasma B cell counts were associated with lower SRI-4 response rates (p<0.05). Elevated baseline IgG levels were associated with increased infection rates over the treatment period (p<0.05), and early greater decreases in IgG levels were associated with higher SRI-4 response rates (p<0.05).

Conclusions Belimumab treatment up to 312 weeks (6 years) resulted in substantial decreases in several circulating B cell subsets and IgG levels. Higher baseline naive B cell counts and IgG levels were associated with improved SRI-4 response and increased infection rates, respectively.

INTRODUCTION

SLE, a chronic autoimmune disease that affects multiple organs, is driven by the abnormal activation of B and T lymphocytes, and is associated with elevated titres of autoantibodies. B lymphocyte stimulator (BlyS; also known as B cell activating factor, or BAFF) is a ligand of the tumour necrosis factor cytokine family that is expressed as membrane-bound or soluble protein. BlyS is a vital B cell survival factor with important roles in B cell maturation and Ig class switching and production. Overexpression of BlyS is thought to be linked to the pathogenesis of SLE and other autoimmune diseases, and increased concentrations of circulating BlyS are correlated with worsening SLE disease activity that is indicative of mild-to-moderate

Key messages

What is already known about this subject?

- B lymphocyte stimulator (BlyS) is essential for B cell maturation and Ig class switching and production.
- Overexpression of circulating BlyS correlates with worsening SLE disease activity and increased risk of SLE flares.
- Belimumab (anti-BlyS) therapy has been evaluated for long-term efficacy and safety and was shown to reduce Ig levels and several circulating B cell subsets in the BLISS-76 Trial.

What does this study add?

- In this post hoc continuation analysis of the BLISS-76 Trial, belimumab treatment up to 312 weeks (6 years) led to decreases in B cell subsets and IgG levels. Elevated baseline naive B cells correlated with improvements in SLE Responder Index response, while elevated baseline IgG titre was associated with poorer SLE Responder Index outcome and greater infection rates.

How might this impact on clinical practice or future developments?

- Assessment of B cell and IgG levels before initiating long-term belimumab therapy may facilitate prediction of response and infection risk of patients with SLE.
Received placebo were switched to belimumab 10 mg/kg intravenous. Of note, for patients who had received placebo in BLISS-76, day 1 was the day of their first dose of belimumab. Following a protocol amendment on 9 March 2011, patients receiving belimumab 1 mg/kg had their dose increased to 10 mg/kg. All belimumab doses were pooled for this analysis.

The study end date was five calendar-years from the date of enrolment of the last patient into the continuation study. Clinical site personnel were blinded to the BLISS-76 parent study treatment until results of the parent study were made public. Written informed consent was obtained from all patients prior to enrolment.

Biomarkers assessment and correlational analyses with SLE disease activity and safety

Assessed biomarkers included change from baseline in circulating concentrations of B cells (CD19+ and CD20+), naïve B cells (CD19+/CD20+/CD27−), memory B cells (CD19+/CD20+/CD27+), activated B cells (CD20+/CD69+), plasmacytoid B cells (CD19+/CD20+/CD138+), SLE subset plasma cells (CD19+/CD27+CD38+CD20−), short-lived plasma B cells (CD19+/CD20−CD27+CD38+), and plasma B cells (CD19+/CD20+/CD138+) over 312 weeks (6 years), and IgG over 284 weeks (~5.5 years). All samples were analysed, and subsequent B cell subset quantification was performed at Q2 Solutions Laboratories as described in the online supplemental methods.

The discrepancy between B cell and IgG level data availabilities derives from differences in the frequency of the measurement of the two biomarkers: while all B cell subsets were measured at baseline and every 24 weeks after first belimumab dose in the continuation study, IgG levels were measured only every 48 weeks (except for study week 1 when measurements were also taken at the week-24 visit) plus at an additional 8-week follow-up visit after the last dose. The 312-week versus 284-week difference derives from patients exiting the study mid-study year without a follow-up visit.

The methods of baseline and early changes (weeks 0–24 of the continuation study) from baseline in biomarkers on SRI-4 responses and the overall number of serious or
severe infections (ie, AEs of special interest in the context of chronic B cell suppression) were evaluated.

Statistical analyses
Analyses were performed on the modified intention-to-treat (mITT) populations from BLISS-76 and its long-term continuation study BEL112233, defined as patients who had received belimumab 1 mg/kg or 10 mg/kg intravenously or placebo. For patients receiving belimumab in BLISS-76, data on biomarker, disease activity and safety from baseline to week 76 were included. For those receiving placebo in BLISS-76, only data collected in the continuation study (after they had switched to belimumab) were included. Thus, for patients who had received placebo in BLISS-76, day 1 was the day of their first belimumab dose. Continuous and categorical data were summarised using means and SD, and counts and percentages, respectively. Tertiles of absolute B cell count and IgG levels as well as tertiles of change from baseline in these measurements were calculated at the end of each 24-week interval in the continuation study. To understand the univariate relationships between tertiles of B cells and IgG levels and efficacy end points, Spearman correlation coefficients and their 95% CIs were calculated. Statistical analyses were conducted for each B cell subset and IgG. The main comparisons were tertile 1 versus tertile 2 and tertile 1 versus tertile 3 for the efficacy end point (ie, SRI-4 response and the occurrence of serious or severe infections).

The rates of SRI-4 response and severe or serious infections were analysed via separate negative binomial regression models for each biomarker with offset log of follow-up time and terms for age, body mass index (BMI), baseline SLEDAI, baseline immunosuppressant use, treatment group, and either baseline biomarker tertile or change from baseline biomarker tertile. Incidence rate ratios and their associated 95% CIs were estimated from these models for each biomarker and covariate of interest, and similar analyses were conducted to determine whether early changes (weeks 0–24 after starting belimumab) from baseline in biomarkers were predictive of SRI-4 response and severe or serious infections.

Patient and public involvement
We did not involve patients and/or the public in the design of this study.

RESULTS
Patients
The global mITT population comprised 819 patients with SLE from the parent BLISS-76 Study (BEL110751), of whom 268 self-selecting patients (from the US sites only; n=177 receiving belimumab and n=91 receiving placebo in the parent study) of the 576 patients who completed BLISS-76 subsequently entered the continuation study (BEL112233). Patient disposition and baseline demographics of the BLISS-76 population who entered the continuation study are shown in table 1.

| Table 1 | Baseline characteristics of patients in the continuation study (n=268) | Patients in the continuation study (n=268) |
|---------|-------------------------------------------------|------------------------------------------|
| Mean (SD) age, years | 42.8 (11.3) | 250 (93.3) |
| Female, n (%) | 268 (100) | 186 (69.4) |
| Race, n (%) | 57 (21.3) | 25 (9.4) |
| Mean (SD) SLE disease duration, years | 7.7 (6.8) | 7.8 (3.9) |
| SELENA-SLEDAI Score, mean (SD) | 0 | 119 (44.4) |
| SDI category, n (%) | ≥1 | 149 (55.6) |
| B cells and biomarkers, mean (SD) | 143.0 (721.2) | 140.7 (720.8) |
| B cells (CD19+), (µL) | 116.6 (108.8) | 24.5 (27.1) |
| Naïve B cells (CD19+/CD20−/CD27−), (µL) | 18.5 (5.1) | 0.3 (0.6) |
| Memory B cells (CD19+/CD20+/CD27+), (µL) | 0.7 (1.3) | 15.2 (6.1) |
| Activated B cells (CD19+/CD20+/CD138+), normalised, (count/mL) | 0.3 (0.6) | 12 (4.5) |
| Plasma B cells (CD19+/CD20+/CD138+), normalised, (count/mL) | 0.7 (1.3) | 44 (16.4) |
| IgG (g/L) | 119 (44.4) | 149 (55.6) |
| Medication, n (%) | 250 (93.3) | 186 (69.4) |
| Steroids | 12 (4.5) | 25 (9.4) |
| Antimalarials | 116 (43.3) | 25 (9.4) |
| CD, cluster of differentiation; SDI, Systemic Lupus International Collaborating Clinics/That American College of Rheumatology (SLICC/ACR) Damage Index; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLE Disease Activity Index. |

Among those who entered the continuation study, 93.3% (n=250/268) were female and mean (SD) age was 42.8 (11.3) years. In total, 69.4%, 21.3% and 9.3% of patients were White, of Black African ancestry/African American or other race, respectively. Overall, patient characteristics were similar between the parent and continuation study populations, and baseline characteristics between placebo and belimumab treatment groups in the parent study were similar. Over the period of both studies, up to eight calendar-years of data were collected, with a median (IQR) belimumab exposure of 310 (209, 364) weeks.

Biomarker responses over time
After 312 weeks (6 years) of continued belimumab dosing (study year 7, week 24), net reductions from baseline of 83%–92% in circulating CD19+, CD20+, and naïve and plasma B cells, 98%–99% in activated and plasmacytoid
B cells, 67% in memory B cells, and 40%–50% in the SLE subset plasma and short-lived plasma B cells were observed (figure 1). The wider range in SLE subset and short-lived plasma B cell reduction compared with other types of B cells was likely due to the comparatively small base numbers of these subsets in the overall B cell population, leading to a higher variability in count. Following 284 weeks (~5.5 years) of belimumab (study year 6, week 48), a 28% reduction from baseline in serum IgG levels was observed (figure 1). Circulating concentrations of all B cell types, except memory B cells, decreased rapidly from baseline in the first 24 weeks of belimumab treatment and then declined more slowly through to week 72 (figure 2). In contrast, memory B cell counts markedly increased during the first 24 weeks, then subsequently declined progressively over time (figure 2).

Beyond 76 weeks (1.5 years) of treatment, B cell numbers either continued to gradually decrease (CD19+, CD20+, memory, activated, plasmacytoid, and plasma B cells) or stabilised (naïve, SLE subset and short-lived plasma B cells; figure 2). By weeks 288 or 312, the decline in numbers of most B cell subsets (naïve, activated, plasmacytoid and plasma B cells) had plateaued, while memory B cells continued to demonstrate a sustained decline, although at a slower rate than at earlier time points. Serum IgG levels continued to progressively decrease throughout the entire study period (figure 2). Anti-double-stranded DNA (anti-dsDNA) IgG antibody levels in a subpopulation of patients (n=135) positive for anti-dsDNA antibodies (230 IU/mL) at baseline also decreased progressively over the follow-up period, but with larger reductions relative to baseline than were observed for total IgG levels (figure 3).

**Baseline biomarker correlation to clinical response or infection risk**

Biomarker changes during belimumab treatment were explored for associations with improvement in SRI-4 and with an increased risk of infections.

**SRI-4 response**

Higher naïve B cell counts at baseline were associated with greater SRI-4 response rates to belimumab (rate ratio per tertile increase 1.10; 95% CI 1.01 to 1.21, p<0.05), whereas higher baseline SLE subset plasma and short-lived plasma B cell counts were associated with lower SRI-4 response rates to belimumab (rate ratio per tertile increase 0.86; 95% CI 0.79 to 0.95 and 0.88; 95% CI 0.80 to 0.96, respectively; each p<0.05) (table 2). Other assessed B cell subsets or IgG at baseline did not significantly correlate with changes in SRI-4 response rates (table 2).

**Serious or severe infections**

Overall rates of serious or severe infection were low and stable across the entire study period (five events occurred, corresponding to a rate of serious or severe infection for any time postbaseline of 0.3 per 100 patient-years), and ranged from 0.4 per 100 patient-years at study years 0–1 to 0 per 100 patient-years at study years 6–7. In total, there was one case each of bacterial sepsis (occurring in study years 4–5; rate of <0.1 per 100 patient-years), genital herpes (occurring in study years 0–1; rate of <0.1 per 100 patient-years), herpes zoster (occurring in study years 1–2; rate of <0.1 per 100 patient-years), and 2 cases of septic shock (occurring in study years 2–3 and 5–6, for...
a combined rate of 0.1 per 100 patient-years). Elevated serum IgG levels, but not B cell counts, at baseline were associated with increased rates of infection over the treatment period (rate ratio per tertile increase 1.75; 95% CI 1.24 to 2.46, p<0.05) (table 2).

Impact of early biomarker changes
Changes in SRI-4 response or infection rates did not appear to be associated with early (within the first 24 weeks of belimumab treatment) changes in biomarkers, except for serum IgG levels. Patients with small changes in serum IgG in the first 24 weeks of belimumab treatment also showed low SRI-4 response rates (rate ratio per tertile increase 0.90; 95% CI 0.82 to 0.98, p<0.05) (table 3).

Impact of covariates on end point-biomarker relationship
Baseline SELENA-SLEDAI Scores ≥10 were associated with a significant increase in SRI-4 responses compared with lower scores (<10), with a rate ratio estimate of ~1.5 in all statistical models. Age and BMI, and the use of immunosuppressants, did not significantly predict SRI-4 responses. Similarly, baseline SELENA-SLEDAI category, immunosuppressant use and BMI did not have a significant impact on the incidence of serious or severe infections over the treatment period. Age was not a significant factor in any of the B cell statistical models but significantly impacted the number of serious or severe infections in the IgG statistical models (rate ratio: 1.37; 95% CI 1.05 to 1.78, per 10 year increase in age, p=0.020).

DISCUSSION
The present analysis builds on previous studies characterising biomarker responses over 2 years and beyond, and clinical responses over 6 years with belimumab therapy.12–15 We observed a marked decline in circulating B cell subset counts during such long-term, continual belimumab treatment, but no subsets were completely depleted. This is in line with observations from BLISS-7612 and phase II studies18 19 of belimumab. B cell subsets show varying degrees of dependence on BLyS, so it is anticipated that their response to belimumab treatment will differ accordingly. In the present study, most B cell subset counts reached a plateau by weeks 288 or 312, and with the exception of memory B cells and serum IgG levels, no further substantial reductions would be expected. Of note, neither SLE subset nor short-lived plasma B cell counts plateaued and instead fluctuated throughout the study period. This, however, may be due to the higher variability in blood cell count for these rare/small subsets.

Table 2  Impact of baseline B cells and IgG on efficacy and safety over the entire treatment period (mITT population)

| Biomarker                          | Number of SRI-4 responses* | Number of serious/severe infections* |
|------------------------------------|----------------------------|-------------------------------------|
| B cells (CD19+)                    | 1.13 (1.03 to 1.23)†       | 0.85 (0.63 to 1.15)                 |
| B cells (CD20+)                    | 1.13 (1.03 to 1.23)†       | 0.71 (0.50 to 1.00)                 |
| Naïve B cells (CD19+/CD20+/CD27−)  | 1.10 (1.01 to 1.21)†       | 0.81 (0.61 to 1.07)                 |
| Memory B cells (CD19+/CD20+/CD27+) | 1.09 (1.00 to 1.18)        | 1.00 (0.70 to 1.44)                 |
| Activated B cells (CD20+/CD69+)    | 1.00 (0.92 to 1.09)        | 1.06 (0.77 to 1.48)                 |
| Plasmacytoid B cells (CD19+/CD20+/CD138+) | 1.07 (0.98 to 1.17) | 1.21 (0.86 to 1.69) |
| SLE subset plasma cells (CD19+/CD27BRIGHT+/CD38BRIGHT+) | 0.86 (0.79 to 0.95)† | 0.97 (0.73 to 1.28) |
| Short-lived plasma B cells (CD19+/CD20−/CD27BRIGHT+) | 0.88 (0.80 to 0.96)† | 0.82 (0.57 to 1.17) |
| Plasma B cells (CD19+/CD20−/CD138+) | 0.93 (0.85 to 1.01) | 1.23 (0.81 to 1.87) |
| IgG                                | 1.01 (0.93 to 1.10)        | 1.75 (1.24 to 2.46)†                |

Rate ratios are calculated from a negative binomial regression model with offset log of follow-up time that includes terms for age, body mass index, baseline SLEDAI, baseline immunosuppressant use, treatment group and baseline biomarker tertile.

Tertile definitions are shown in online supplemental table S1.

*Rate ratio per tertile increase and 95% CIs based on baseline biomarker tertile.
†Statistical significance at 0.05 level.
CD, cluster of differentiation; mITT, modified intent-to-treat; SLEDAI, SLE Disease Activity Index; SRI, SLE Responder Index responses.
In earlier studies of belimumab, the cause of this decline, and a similar pattern has generally been observed by belimumab, peaking at week 24, was followed by a sustained time frame, anti-dsDNA antibodies at baseline decreased 3), demonstrating that long-term belimumab treatment preferentially decreased these SLE-positive B cells essential for humoral immunity and that belimumab might preferentially reduce B cells with antigen specificities or functionality redundant for humoral immunity. However, in the present analysis, elevated serum IgG levels at baseline were associated with significantly increased rates of infection over the treatment period. This may be related to patients having more severe disease (ie, high baseline SELENA-SLEDAI Scores) at study entry. Higher disease activity and more refractory disease may in turn increase the likelihood of patients receiving more potent and higher doses of immunosuppressive therapies and, therefore, having an increased susceptibility to infections. While this hypothesis could not be confirmed within the confines of this study, such a relationship of serological activity (low complement levels and elevated titres of anti-dsDNA antibodies) with increased baseline IgG, SELENA-SLEDAI Scores, and immunosuppressant use was demonstrated previously in the pooled BLISS-52 and BLISS-76 population. Long-term extension studies showed reductions in immunosuppressant use with belimumab, and lower incidence of infections, including serious infections. In the current study, immunosuppressant use did not have a significant impact on rates of infections.

Smaller reductions or increases in serum IgG levels in the first 24 weeks were associated with significantly lower SRI-4 response rates to belimumab. This finding is consistent with an analysis of biomarkers over the first 76 weeks in which belimumab-treated patients with normalisation of IgG levels had significantly greater SRI response rates than did patients without normalisation at weeks 24 and 40.

An initial increase in memory B cells in response to belimumab, peaking at week 24, was followed by a sustained decline, and a similar pattern has generally been observed in earlier studies of belimumab. The cause of this response is unclear; the time profile is consistent with a transient redistribution of memory B cells from lymphoid tissues to the circulation, combined with a slow decrease in total numbers. The results presented (ie, a substantial reduction of memory B cells after multiple years of treatment) are in contrast with reports of their limited dependence on BLyS for survival. However, this seeming discrepancy could be explained if the survival of memory B cells is BLyS-independent but the survival of their precursors is not. In that case, after BLyS reduction by belimumab, the pool of memory B cells would not be adequately replenished and would decrease over time. Low IgG levels are considered a risk factor for infections. In this study, a median reduction of IgG levels of <30% to a median level of 10.30 g/L (8.57 g/L at 25th percentile) after approximately 5.5 years of belimumab treatment did not raise safety concerns for a typical patient, based on IgG lower limits of normal of 6–7 g/L, a result in line with previous reports. During the same time frame, anti-dsDNA IgG antibody levels in patients positive for anti-dsDNA antibodies at baseline decreased by 64.9% (figure 3), demonstrating that long-term belimumab treatment preferentially decreased these SLE-specific autoreactive antibodies.

B cell reductions from baseline were not correlated with any significant changes in the known safety profile of belimumab. Despite continued reductions in B cell subsets, there was no trend for increased rates of serious or severe infections with longer treatment durations.

### Table 3

| Biomarker                                      | Number of SRI-4 responses* | Number of serious/severe infections* |
|------------------------------------------------|---------------------------|-------------------------------------|
| B cells (CD19+)                                | 0.97 (0.89 to 1.05)       | 1.25 (0.88 to 1.79)                 |
| B cells (CD20+)                                | 0.96 (0.88 to 1.05)       | 1.16 (0.83 to 1.64)                 |
| Naive B cells (CD19+/CD20+/CD27−)              | 0.94 (0.85 to 1.03)       | 1.18 (0.78 to 1.78)                 |
| Memory B cells (CD19+/CD20+/CD27+)             | 0.98 (0.89 to 1.07)       | 1.20 (0.87 to 1.66)                 |
| Activated B cells (CD20+/CD69+)                | 0.93 (0.85 to 1.01)       | 1.12 (0.77 to 1.62)                 |
| Plasmacytoid B cells (CD19+/CD20+/CD138+)      | 0.92 (0.85 to 1.01)       | 1.19 (0.86 to 1.65)                 |
| SLE subset plasma cells (CD19+/CD27BRIGHT+/38BRIGHT+) | 1.00 (0.92 to 1.09)   | 1.03 (0.73 to 1.45)                 |
| Short-lived plasma B cells (CD19+/CD20−/CD27BRIGHT+) | 1.01 (0.92 to 1.10)   | 0.95 (0.69 to 1.32)                 |
| Plasma B cells (CD19+/CD20−/CD138+)            | 0.98 (0.90 to 1.07)       | 1.15 (0.80 to 1.66)                 |
| IgG                                            | 0.90 (0.82 to 0.98)†       | 0.83 (0.59 to 1.18)                 |

Rate ratios are calculated from a negative binomial regression model with offset log of follow-up time that includes terms for age, body mass index, baseline SLEDAI, baseline immunosuppressant use, treatment group and change from baseline at 6 months biomarker tertile. Tertile definitions are shown in online supplemental table S1. Most extreme reductions are in tertile 1 (ie, a value of 0.90 indicates that the probability of response is reduced by 0.9 for a patient in tertile 2 compared with tertile 1, and by 0.81=0.9⁰.⁹ for patients in tertile 3 compared with tertile 1 while holding all other variables in the model constant).

*Rate ratio per tertile increase and 95% CIs based on the percent change from baseline at 6 months biomarker tertile.
†Statistical significance at 0.05 level.

CD, cluster of differentiation; mITT, modified intention-to-treat; SLEDAI, SLE Disease Activity Index; SRI, SLE Responder Index responses.
In the present study, elevated baseline naïve B cell counts were associated with improved SRI-4 response rates, while higher baseline SLE subset plasma and short-lived plasma B cell counts were associated with poorer SRI-4 response rates. None of the other B cell subsets significantly influenced SRI-4 response. Improvements in clinical response could be due in part to reductions in certain BlyS-dependent B cell populations leading to a reduction in inflammatory cytokines and/or autoantibody production.

Higher baseline SELENA-SLEDAI Scores (≥10 vs 6–9) used as covariates on end point-biomarker relationships were associated with a higher SRI-4 response rate. This relationship has been shown elsewhere in univariate analyses of likelihood of response and baseline disease activity and may reflect the effect of analysing an absolute threshold (4-point reduction as part of the SRI-4) with more room for improvement or a greater involvement of BlyS-driven pathology in patients with high-disease activity as compared with patients with lower-disease activity.

There are several limitations inherent to the study. As a post hoc analysis, the study was not formally designed to assess the relationship between numbers of B cells, IgG concentrations, and efficacy and safety end points. However, assessment of absolute numbers/levels of these biomarkers would be of interest to evaluate in the future, because this may allow potential thresholds to be established to assist clinicians in relating biomarker levels to infectious events or other AEs observed in clinical practice. At the time of the study, the differentiation between naïve B cells and double-negative memory B cells had not been well established and, accordingly, was not studied. As such, further investigation is warranted. However, a recent analysis of samples from patients with lupus nephritis or with SLE demonstrated that both unswitched and switched (IgG1, IgG2, IgA1, IgA2+) memory B cells increased after belimumab treatment. Increases of both preswitched (IgD+CD27+) and postswitched (IgD–CD27+) memory B cells have also been demonstrated for another BlyS/BAFF antagonist. At baseline, there may have been an existing effect of prior therapies on B cell subsets, and no adjustments for multicollinearity were made, increasing the chance of introducing a type 1 error. When analysing the B cell counts and serum IgG levels after 312 weeks (6 years) of belimumab treatment, the complications subpopulation represents <45% of the 268 patients who initially entered the continuation study. This subpopulation may not be representative of the entire study population, as there may have been a natural selection bias towards those who had good initial responses to belimumab and few AEs, including infection. This may have contributed to the low rates of serious or severe infection as an AE. As such, these data should be interpreted with caution. However, this study’s design is similar to that of the two belimumab phase II continuation studies, in which patients also switched treatment (from placebo to belimumab or from lower to higher belimumab dose). In line with results from this study, the two phase II studies showed increases in SRI responses, and reductions in flares, AE rates and serological biomarker levels, over time. This analysis only focused on the B cell population in the blood and did not analyse B cell subsets in the secondary lymphoid tissue where the immune response is facilitated. Furthermore, the effect of belimumab treatment on T cell counts was not assessed; however, belimumab has been demonstrated to exert only mild effects on T cell populations, if any, and these appear to be restricted to the subset of CD8 + effector memory T cells. It is also pertinent to note that data may have differed between those initially enrolled into belimumab 1 mg vs 10 mg groups compared with placebo. The effect of the 76-week delay in the placebo group starting belimumab treatment was not formally investigated; however, B cell and IgG changes for placebo and active groups were similar (with regard to the timing and magnitude of the response) after accounting for the time shift, justifying the pooling of these groups in this analysis. Moreover, results from phase III studies showed similar reductions in multiple B cells and plasma B cell subsets with belimumab for patients who received 1 mg/kg dose to those in patients who received the 10 mg/kg dose. Furthermore, the patients enrolled in the continuation study were a subpopulation of the initial study, and of these, some did not have SRI-4 and biomarker data up to 312 weeks (6 years) available for analysis.

CONCLUSIONS

Belimumab treatment up to 284 (~5.5 years) and 312 weeks (6 years) resulted in substantial decreases in most of the assessed circulating B cell subset counts and in serum IgG levels. The observed decreases in B cell subsets and IgG levels with long-term belimumab treatment are in line with its mechanism of action and with observations from previous analyses of patients with SLE. Elevated baseline naïve B cells were associated with improvements in SRI-4, while elevated baseline SLE subset plasma and short-lived plasma B cells, and early increases in IgG levels, were associated with poorer SRI-4 response. Elevated baseline IgG titre was associated with significantly increased infection rates. Assessment of these biomarkers before initiating long-term belimumab treatment may have value in predicting response and infection risk and may also assist in counselling and management of patients with SLE.

Author affiliations

1Clinical Pharmacology Modeling & Simulation, GlaxoSmithKline, Research Triangle Park, North Carolina, USA
2Biostatistics, GlaxoSmithKline, Collegeville, Pennsylvania, USA (At the time of the study)
3Biostatistics, GlaxoSmithKline, Chapel Hill, North Carolina, USA (At the time of the study)
4Freimuth Biopharmaceutical Consulting, Gaithersburg, Maryland, USA (At the time of the study)
5Research & Development, GlaxoSmithKline, Collegeville, South Carolina, USA
6Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA

Struempfer H, et al. Lupus Science & Medicine 2022;9:e000499. doi:10.1136/lupus-2021-000499
Acknowledgements  The authors thank Q Solutions Laboratories for conducting sample analysis of the B cell subset quantification, and Dr Thi-Sau Migone for her input in the study design and data analysis. Medical writing assistance was provided by Jennie McLean, PhD, of Fishawk Indicia Ltd, UK, part of Fishawk Health, and was funded by GlaxoSmithKline (GSK).

Contributors  DAR, WWF and WS were involved in study concept and/or design; WS was involved in acquisition of data; and DAR, HS, LE, MK, WWF and WS contributed to analysis and/or interpretation of data. HS is the guarantor. All authors reviewed the final draft of the manuscript and approved it for submission.

Funding  Study BEI12233 (ClinicalTrials.gov identifier NCT00724867) and its BLISS-76 parent study (BEI110751; ClinicalTrials.gov identifier: NCT00410384) were funded by GSK.

Competing interests  HS and DAR are employees of and own stocks/shares in GSK. MK and LE are former GSK employees and LE owns stocks/shares in GSK. WWF was an employee of HGS at the time of the BLISS-76 Trial and is a former GSK employee. WS has received research support from GSK and was supported in part by grants ULTR0001150 and ULTR0001130 from the National Center for Advancing Translational Science (NCATS) of the US National Institutes of Health.

Patient consent for publication  Not applicable.

Ethics approval  This study involves human participants and the study was performed in accordance with the principles of the Declaration of Helsinki. All sites (Schulman Associates Institutional Review Board, Biomedical Research Alliance of New York, LLC, Institutional Review Board; NYU School of Medicine Institutional Review Board; University of Kansas Medical CenterCentre - Human Subjects Committee; Oklahoma Medical Research Foundation - Institutional Review Board, Institutional Review Board, Institutional Review Board - The Johns Hopkins University East Baltimore Campus ([Central Office]); University of Chicago Institutional Review Board; Western Institutional Review Board ([WIRB]); Ochsner Clinic Foundation Institutional Review Board; Wake Forest Baptist Health Institutional Review Board; Montefiore Medical Center, Internal Review Board; Cedars Sinai Medical Center Institutional Review Board; Gundersen Clinic Limited, Human Subjects Committee; University of Arizona Institutional Review Board; Medical University of South Carolina Office of Research Integrity; Office of Human Research Ethics, The University of North Carolina at Chapel Hill; MedStar Research Institute; Institutional Review Board, University Hospital of Brooklyn, Kings County Hospital; University of Michigan Medical School IRB/BMED; University of Pittsburgh Institutional Review Board; University of Southern California ([USC] Health Sciences Campus Institutional Review Board) maintained ethics committee and institutional review board approval.

Provenance and peer review  Not commissioned; externally peer reviewed.

Data availability statement  Data are available upon reasonable request.

Anonymised individual participant data and study documents are available upon reasonable request. Medical writing assistance was provided by Jennie McLean, PhD, of Fishawk Indicia Ltd, UK, part of Fishawk Health, and was funded by GlaxoSmithKline (GSK).

Supplemental material  This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs  Herbert Struempfer http://orcid.org/0000-0003-3011-1572
William Stohl http://orcid.org/0000-0002-8272-7873

REFERENCES
1. Cancro MP, D’Cruz DP, Khamashita MA. The role of B lymphocyte stimulator (BLYS) in systemic lupus erythematosus. J Clin Invest 2009;119:1066–73.
2. D’Cruz DP, Khamashita MA, Hughes GRV. Systemic lupus erythematosus. Lancet 2007;369:587–96.
3. Batten M, Groom J, Cachero TG, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192:1543–66.
4. Castigli E, Wilson SA, Scott S, et al. Taci and BAFF-R mediate isotype switching in B cells. J Exp Med 2005;201:35–9.
5. Sinko AG, Tschopp J, Schneider P, et al. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol 2002;32:2004–10.
6. Steri M, Orrù V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmune risk. N Engl J Med 2017;376:1615–26.
7. Petr MI, van Vollenhoven RF, Buyn J, et al. Baseline predictors of systemic lupus erythematosus: flares data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum 2013;65:2143–53.
8. GlaxoSmithKline. Prescribing information. 2020. Available: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_ Information/Benlysta/pdf/BENLYSTA-PI-MF-IFU.PDF [Accessed Feb 2021].
9. GlaxoSmithKline. Benlysta summary of product characteristics. Available: https://www.eea.europa.eu/en/documents/product-information/benlysta-epar-product-information_en.pdf [Accessed Feb 2021].
10. Pharmaceuticals and Medical Devices Agency (PMDA). Benlysta report on deliberation results. Available: https://www.pmda.go.jp/files/000235894.pdf [Accessed Feb 2021].
11. Petr MI, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453–9.
12. Furie R, Petrozzi M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3518–30.
13. Furie RA, Wallace DJ, Aranov C, et al. Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six-week phase III parent study in the United States. Arthritis Rheumatol 2018;70:368–77.
14. Navarre SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–31.
15. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328–37.
16. Jacoboi AM, Oendalani M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332–42.
17. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143–51.
18. Jacoboi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010;62:201–10.
19. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168–78.
20. Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and April. J Immunol 2008;180:3655–9.
21. Scholz JL, Crowley TE, Tomayko MM, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A 2008;105:15517–22.
22. Alamghouth I, Su J, Johnson SR, et al. Acquired low immunoglobulin levels and risk of clinically relevant infection in adult patients with systemic lupus erythematosus: a cohort study. Rheumatology 2021;60:1456–64.
23. Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014;41:300–9.
24. Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheumatol 2012;64:3864–73.
25. Cancro MP. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol 2009;9:657–61.
26. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Arthritis Rheum 2012;64:1343–9.
27. Dönner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 2006;77:3–11.
Immunology and inflammation

28 Arends EJ, Zlei M, Tipton CM, et al. POS0680 BELIMUMAB ADD-ON THERAPY MOBILISES MEMORY B CELLS INTO THE CIRCULATION OF PATIENTS WITH SLE. *Ann Rheum Dis* 2021:80

29 Stohl W, Merrill JT, Looney RJ, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. *Arthritis Res Ther* 2015;17:1–14.

30 Regola F, Piantoni S, Lowin T, et al. Association between changes in BLyS levels and the composition of B and T cell compartments in patients with refractory systemic lupus erythematos treated with belimumab. *Front Pharmacol* 2019;10:433.

31 Struemper H, Freimuth W, Kleoudis C. Sustained reductions in circulating B cell populations and immunoglobulin G levels with long-term belimumab treatment in patients with systemic lupus erythematosus. *Arthritis Rheum* 2013;65:S680.